Licensing deal for Basilea in sight

13 January 2012

The completion of the pneumonia data audit and confirmation of the timeline for Switzerland-based Basilea’s (SIX: BSLN) European data filing of ceftobiprole brings the company a step closer to achieving a licensing deal for the drug, comment analysts at Edison Investment Research. Global sales of other broad spectrum antibiotics are in a high growth phase.

The investment case for Basilea is strongly dependent on securing US and/or European partnerships for ceftobiprole, the analysts say. Meanwhile, the US future for the drug hinges on a decision from the US Food and Drug Administration on the need for further trials. Ceftobiprole was formerly partnered with US drug major Johnson & Johnson, which returned rights to the MRSA drug candidate a couple of years ago (The Pharma Letter February 22, 2010)

The independent data audit of ceftobiprole in hospital and community acquired pneumonia is now complete. However, there will be six months for data analysis before data filing with the European Medicines Agency in the second half of 2012.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >